Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
0.7488
-0.0765 (-9.27%)
At close: Jun 2, 2026, 4:00 PM EDT
0.5990
-0.1498 (-20.01%)
Pre-market: Jun 3, 2026, 8:50 AM EDT
Soligenix Employees
As of December 31, 2025, Soligenix had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees decreased by 2 or -12.50% compared to the previous year.
Employees
14
Change (1Y)
-2
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$782,434
Market Cap
7.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | -2 | -12.50% | 13 | 1 |
| Dec 31, 2024 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2023 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2022 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2021 | 15 | -3 | -16.67% | 13 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PMGC Holdings | 34 |
| Imunon | 20 |
| Genprex | 13 |
| NuCana | 12 |
| Quoin Pharmaceuticals | 6 |
| Enveric Biosciences | 6 |
| Creative Medical Technology Holdings | 4 |
| Addex Therapeutics | 2 |
SNGX News
- 8 days ago - Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo - PRNewsWire
- 26 days ago - Soligenix reports Q1 EPS (28c) vs. (97c) last year - TheFly
- 26 days ago - Soligenix Announces Recent Updates and First Quarter 2026 Financial Results - PRNewsWire
- 26 days ago - Soligenix Quarterly report: Q1 2026 - Filings
- 26 days ago - Soligenix Earnings release: Q1 2026 - Filings
- 4 weeks ago - Soligenix price target lowered to $1.50 from $10 at Alliance Global - TheFly
- 5 weeks ago - Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma - TheFly
- 5 weeks ago - Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire